The Effect of Benralizumab on Exercise-induced Bronchoconstriction
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Severe asthma affects 5-10% of more than 300 million asthmatics. Ten to twenty percent of
individuals suffering from asthma do not respond well to current treatment due to the
complexity of the different mechanisms underlying asthma pathogenesis, and sometimes due to
an insufficient effect of treatment on underlying airway inflammation. Consequently, some
asthmatics have poorer quality of life due to: frequent asthma symptoms, regular medical or
emergency visits, limitation in their activities of daily living, including exercise. It is
believed that the benralizumab can help to reduce airway inflammation and thus improve
exercise tolerance in individuals with asthma. The main objective of this study is to
determine the effect of benralizumab on exercise-induced bronchoconstriction (EIB) and
exercise tolerance in moderate to severe eosinophilic asthmatics, in comparison with baseline
values and a placebo treatment.